New nerve block aimed at cutting opioid use after bypass

NCT ID NCT07587320

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a set of nerve blocks (injections of numbing medicine) right after anesthesia but before surgery can reduce pain and the need for opioid painkillers after coronary artery bypass grafting. 56 adults scheduled for elective bypass surgery will be randomly assigned to receive either the nerve blocks plus standard pain care, or standard care alone. The main goal is to measure total opioid use in the first 48 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nerve block package (ultrasound-guided injections of local anesthetic)
What this could lead to
If it works, this could offer a better way to manage pain after heart bypass surgery, reducing the need for strong painkillers like opioids.
What could go wrong
This is a small, early-phase study (56 people) testing a procedure, not a drug. The nerve blocks may not provide significant extra pain relief, and there are small risks like bleeding or infection at the injection sites.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY BYPASS GRAFT (CABG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Health Sciences, Diyarbakir Gazi Yasargil Training and Research Hospital

    RECRUITING

    Diyarbakır, Diyarbakır, Turkey (Türkiye)

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.